T-cell branched glycosylation as a mediator of colitis-associated colorectal cancer progression: a potential new risk biomarker in inflammatory bowel disease - Scorecard - MDSpire
Advertisement
T-cell branched glycosylation as a mediator of colitis-associated colorectal cancer progression: a potential new risk biomarker in inflammatory bowel disease
Clinical Scorecard: T-cell Glycosylation Patterns as Influencers of Colitis-Related Colorectal Cancer Development: A Potential Biomarker for Inflammatory Bowel Disease Risk
At a Glance
Category
Detail
Condition
Colitis-associated colorectal cancer (CAC) developing from inflammatory bowel disease (IBD)
Key Mechanisms
Dynamic regulation of branched N-glycosylation on colonic T cells influencing immune response and tumor progression
Target Population
Patients with inflammatory bowel disease, especially those with long-standing colitis
Care Setting
Gastroenterology and oncology clinical settings focusing on IBD management and colorectal cancer surveillance
Key Highlights
Branched N-glycans on colonic T cells increase progressively from colitis to dysplasia and cancer, imposing inhibitory effects on T-cell antitumor activity.
Deletion of branched N-glycans in Mgat5 knockout mice suppresses CAC by enhancing CD8+ and γδ T cell infiltration and antitumor immunity.
Branched N-glycosylation levels in inflamed IBD lesions predict CAC progression with 83.3% sensitivity and 67.9% specificity when combined with age at diagnosis.
Guideline-Based Recommendations
Diagnosis
Assess branched N-glycosylation levels in colonic T cells from inflamed lesions of IBD patients as a biomarker for CAC risk stratification.
Combine glycosylation profiling with clinical factors such as age at diagnosis to improve early identification of high-risk patients.
Management
Implement enhanced surveillance and preventive strategies in IBD patients exhibiting high branched N-glycosylation levels.
Consider targeting glycosylation pathways to modulate T-cell immune responses as a potential therapeutic approach.
Monitoring & Follow-up
Regularly monitor glycosylation patterns in colonic immune cells during IBD progression to detect early preneoplastic changes.
Integrate glycosylation biomarker assessment into routine endoscopic surveillance protocols for IBD patients.
Risks
Long-standing and extensive colitis increases risk of CAC development.
Male sex, family history of CRC, colonic strictures, previous dysplasia, and primary sclerosing cholangitis are additional risk factors.
Patient & Prescribing Data
IBD patients at risk of progression to colitis-associated colorectal cancer
Branched N-glycosylation profiling may guide personalized surveillance and preventive interventions; modulation of glycosylation could enhance antitumor immunity.
Clinical Best Practices
Incorporate branched N-glycosylation assessment of colonic T cells into risk stratification models for CAC in IBD patients.
Use combined biomarker and clinical data to tailor surveillance intervals and preventive care.
Explore glycoengineering approaches to restore effective T-cell antitumor responses in CAC prevention.
by Eduarda Leite-Gomes, Mariana C Silva, Ana M Dias, Ângela Fernandes, Guilherme Faria, Rafaela Nogueira, Beatriz Santos-Pereira, Henrique Fernandes-Mendes, Catarina M Azevedo, Joana Raposo, Julian López Portero, Tania de Alda Catalá, Carlos Taxonera, Paula Lago, Maria J Fernandez-Aceñero, Isadora Rosa, Ricardo Marcos-Pinto, Salomé S Pinho
